CA-RUBICON-CARBON
9.7.2024 15:01:29 CEST | Business Wire | Press release
Rubicon Carbon, a carbon credit management firm, today announced a new partnership with Formula E Champion and ABT CUPRA driver Lucas di Grassi to purchase carbon credits using the company’s platform. Di Grassi is the first Formula E driver to offset his carbon footprint by personally investing in carbon credits.
Di Grassi built his own Rubicon Carbon Tonne (RCT), a diversified and actively managed portfolio of carbon credits that includes carbon removal, nature-based avoidance, and industrial avoidance projects. Through RCTs, buyers reduce risk and increase optionality and price certainty.
"We are excited to support Lucas and Formula E, who share our values in building a low-carbon future," said Tom Montag, CEO of Rubicon Carbon. "This partnership perfectly aligns with our mission to innovate and lead in the fight against climate change, and we look forward to helping Lucas on his path to decarbonizing the mobility and racing industries.”
To celebrate the partnership, di Grassi’s car and helmet proudly displayed Rubicon Carbon logos at last month’s Hankook Portland E-Prix in Portland, Oregon. The collaboration between Rubicon Carbon and di Grassi exemplifies the potential of sports partnerships to drive positive environmental change.
As an activist in mobility technology and the first Formula E driver to publicly sever ties with industries that do not prioritize sustainability, di Grassi has set a precedent for how to champion environmental responsibility as a professional athlete.
Speaking on the partnership, di Grassi noted, “I am proud to be the first driver to offset all the carbon I have emitted from traveling around the world since my first Formula E race in Beijing. Working with (Rubicon Carbon CEO) Tom Montag and his entire team is the perfect partnership for me, as Rubicon Carbon is the most qualified and credible carbon credit management firm in the world. In line with the values and objectives of Formula E, I drive an electric car and have adapted my lifestyle. But still, credible carbon avoidance and removal is the only way to do the sport we love and be responsible for our environment at the same time. I would be delighted if many other athletes, not only in Formula E, would consider the same path.”
This partnership follows Rubicon’s recent investments in carbon projects across the globe, including a large-scale ecosystem restoration project in Panama in partnership with Ponterra, Microsoft, and Carbon Streaming, a 250K+ acres restoration project in South Africa led by Imperative, and a collaboration with YvY Capital to scale up carbon investments in Brazil.
For more information on Rubicon Carbon, visit the website or follow on LinkedIn.
About Lucas di Grassi:
Lucas di Grassi is a founding member of Formula E, has competed in every race up until now and is the most successful driver on the grid in terms of podium positions. He was winner of the first ever race in Beijing 2014, Champion in the 2016/2017 and teams' Champion in 2017/2018. In addition to his role as an ABT CUPRA driver, Lucas di Grassi is an entrepreneur for innovation, sustainability and electric mobility. As co-founder of Zero Summit he is organizing technology and business panels for a zero-carbon future in many countries around the world. Since 2018, Lucas di Grassi is an official United Nations Ambassador for Clean Air. Lucas di Grassi lives in Monaco together with his wife Bianca, his son Leonardo and his daughter Beatriz.
About Formula E:
As the world’s first all-electric FIA World Championship and the only sport certified net zero carbon since inception, the ABB FIA Formula E World Championship brings dramatic racing to the heart of some of the world’s most iconic cities providing an elite motorsport platform for the world’s leading automotive manufacturers to accelerate electric vehicle innovation. The Formula E network of teams, manufacturers, partners, broadcasters, and host cities are united by a passion for the sport and belief in its potential to accelerate sustainable human progress and create a better future for people and planet.
About Rubicon Carbon:
Rubicon Carbon is a carbon credit management firm that partners with the world’s largest enterprises to help them achieve their sustainability goals while driving global decarbonization. Backed by TPG Rise Climate and led by top executives from across finance, technology, and climate science, Rubicon Carbon delivers innovative carbon credit solutions to global businesses while unlocking decarbonization projects at scale, all backed by rigorous in-house scientific diligence. For more information, visit www.rubiconcarbon.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709047754/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom